Innate Pharma Files 2025 Annual Reports
Analysis based on 7 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026
The filing of these annual reports by Innate Pharma ensures compliance with regulatory requirements in both France and the United States, providing transparency to investors. This routine event typically has a neutral impact on the market sentiment for Innate Pharma, as it is an expected part of being a publicly traded company.
Innate Pharma, a global clinical-stage biotechnology company, announced the filing of its 2025 Universal Registration Document with the France — Autorité des marchés financiers in France and its 2025 Form 20-F annual report with the United States — United States Securities and Exchange Commission. These filings, made on April 1, 2026, include the annual financial report, management report, corporate governance report, and statutory auditors' report. Innate Pharma is headquartered in Marseille, France, with a US office in Rockville, MD, and is listed on Euronext Paris and Nasdaq. The company is developing immunotherapies for cancer patients and has collaborations with companies like Sanofi and AstraZeneca.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard